Physician profile
Rafael Rojas
NPI 1326285636
$681.04
in general payments reported to CMS, 2019-2025
16 companies · $373 in 2025
The $373 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $86.66 · 2022: $74.68 · 2023: $42.02 · 2024: $105 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $519.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $198.41 | 2021-2024 | Invega Sustenna |
| Janssen Biotech, INC. | $138.54 | 2025 | Tecvayli, Darzalex |
| Pfizer INC. | $44.92 | 2025 | |
| Abbvie INC. | $42.02 | 2023 | |
| Incyte Corporation | $26.75 | 2025 | Zynyz, Monjuvi |
| Geron Corporation | $24.82 | 2025 | Rytelo |
| Immunocore Limited | $22.94 | 2024 | Kimmtrak |
| Tempus Ai, INC | $22.59 | 2024 | |
| Alkermes, INC. | $22.31 | 2024 | Aristada, Lybalvi |
| Sumitomo Pharma America, INC. | $21.56 | 2025 | Gemtesa |
| Argenx US, INC. | $20.92 | 2025 | Vyvgart |
| Merck Sharp & Dohme LLC | $20.84 | 2025 | Keytruda |
| Tersera Therapeutics LLC | $20.27 | 2025 | Zoladex |
| Pharmacosmos Therapeutics INC. | $19.83 | 2025 | Monoferric |
| Tolmar, INC. | $19.46 | 2025 | Eligard |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $14.86 | 2025 | Blincyto, Kyprolis, Imdelltra (Amg757) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Rojas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.